Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Ryanodex vs dantrolene cost?Fedratinib synthesis patent targetgen?Belbuca 75 mcg film cost?Us glucagon delivery devices market?Rhopressa netarsudil fda approval date?
See the DrugPatentWatch profile for onivyde
Information regarding discounts on onivyde is not available in the provided documents.
Onivyde (nal-IRI) is a chemotherapy drug used to treat certain types of cancer. It is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [1].
Onivyde is manufactured by Servier Pharmaceuticals [2].
Specific patent expiration dates for Onivyde are not detailed in the provided information. However, for comprehensive patent information and expiry timelines, resources like DrugPatentWatch.com can offer insights [3].
Onivyde is approved for the treatment of adult patients with: * Metastatic pancreatic adenocarcinoma, in combination with fluorouracil and leucovorin [1]. * Gastric or gastroesophageal junction adenocarcinoma, in combination with fluoropyrimidine-based chemotherapy [1].
Other Questions About Onivyde :